JP2005537283A - 胃食道逆流（ｇａｓｔｒｏｅｓｏｐｈａｇａｌｒｅｆｌｕｘ）診断用生分解性マイクロスフェア - Google Patents
胃食道逆流（ｇａｓｔｒｏｅｓｏｐｈａｇａｌｒｅｆｌｕｘ）診断用生分解性マイクロスフェア Download PDFInfo
- Publication number
- JP2005537283A JP2005537283A JP2004524029A JP2004524029A JP2005537283A JP 2005537283 A JP2005537283 A JP 2005537283A JP 2004524029 A JP2004524029 A JP 2004524029A JP 2004524029 A JP2004524029 A JP 2004524029A JP 2005537283 A JP2005537283 A JP 2005537283A
- Authority
- JP
- Japan
- Prior art keywords
- aspiration
- microspheres
- gastroesophageal reflux
- microns
- diameter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 31
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title claims abstract description 13
- 238000003745 diagnosis Methods 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 12
- 239000004626 polylactic acid Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 229920000388 Polyphosphate Polymers 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 229920001519 homopolymer Polymers 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 239000001205 polyphosphate Substances 0.000 claims description 2
- 235000011176 polyphosphates Nutrition 0.000 claims description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 206010003504 Aspiration Diseases 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 210000001132 alveolar macrophage Anatomy 0.000 description 12
- 239000002904 solvent Substances 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- 241000699800 Cricetinae Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 210000003437 trachea Anatomy 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000003610 charcoal Substances 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JDTUPLBMGDDPJS-UHFFFAOYSA-N 2-methoxy-2-phenylethanol Chemical compound COC(CO)C1=CC=CC=C1 JDTUPLBMGDDPJS-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012760 immunocytochemical staining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QEDVGROSOZBGOZ-WXXKFALUSA-N (e)-but-2-enedioic acid;n-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide Chemical compound OC(=O)\C=C\C(O)=O.C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1.C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1 QEDVGROSOZBGOZ-WXXKFALUSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 208000003241 Fat Embolism Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 208000012274 Laryngotracheoesophageal cleft Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010044310 Tracheo-oesophageal fistula Diseases 0.000 description 1
- 208000005864 Tracheoesophageal Fistula Diseases 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010051895 acute chest syndrome Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000016274 isolated tracheo-esophageal fistula Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000025644 recurrent pneumonia Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15090602A IL150906A0 (en) | 2002-07-25 | 2002-07-25 | Diagnostic microspheres |
| PCT/IL2003/000552 WO2004011035A2 (en) | 2002-07-25 | 2003-07-03 | Bio-degradable microspheres for diagnosing gastroesophagal reflux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005537283A true JP2005537283A (ja) | 2005-12-08 |
| JP2005537283A5 JP2005537283A5 (enExample) | 2006-08-24 |
Family
ID=29596364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004524029A Pending JP2005537283A (ja) | 2002-07-25 | 2003-07-03 | 胃食道逆流（ｇａｓｔｒｏｅｓｏｐｈａｇａｌｒｅｆｌｕｘ）診断用生分解性マイクロスフェア |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8231860B2 (enExample) |
| EP (1) | EP1575620B1 (enExample) |
| JP (1) | JP2005537283A (enExample) |
| AU (1) | AU2003242957A1 (enExample) |
| IL (1) | IL150906A0 (enExample) |
| WO (1) | WO2004011035A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020037100A (ja) * | 2018-08-31 | 2020-03-12 | ポール・コーポレーションＰａｌｌ Ｃｏｒｐｏｒａｔｉｏｎ | 耐塩性アニオン交換媒体 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050283096A1 (en) | 2004-06-17 | 2005-12-22 | Bloorview Macmillan Children's Centre, A Corp. Registered Under The Ontario Corporations Act | Apparatus and method for detecting swallowing activity |
| US9138171B2 (en) | 2004-06-17 | 2015-09-22 | Holland Bloorview Kids Rehabilitation Hospital | System and method for detecting swallowing activity |
| EP2046397A2 (en) * | 2006-07-19 | 2009-04-15 | SmithKline Beecham Corporation | Method for radiolabeling formulations for gamma scintigraphy assesment |
| US8992446B2 (en) | 2009-06-21 | 2015-03-31 | Holland Bloorview Kids Rehabilitation Hospital | Procedure for denoising dual-axis swallowing accelerometry signals |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06504274A (ja) * | 1991-01-07 | 1994-05-19 | シンジェニックス・リミテッド | 微細粒子 |
| JPH06506254A (ja) * | 1991-04-05 | 1994-07-14 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 低密度の微細球およびコンピューター断層撮影用コントラスト剤としてのそれらの使用 |
| JPH10273447A (ja) * | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
| JP2002507976A (ja) * | 1997-06-27 | 2002-03-12 | ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド | 薬理薬物の新規製剤、その製造法及びその使用法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2659554B1 (fr) | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| CA2263765C (en) | 1996-08-19 | 2010-03-30 | Vivorx Pharmaceuticals, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
-
2002
- 2002-07-25 IL IL15090602A patent/IL150906A0/xx not_active IP Right Cessation
-
2003
- 2003-07-03 AU AU2003242957A patent/AU2003242957A1/en not_active Abandoned
- 2003-07-03 US US10/522,200 patent/US8231860B2/en not_active Expired - Fee Related
- 2003-07-03 JP JP2004524029A patent/JP2005537283A/ja active Pending
- 2003-07-03 WO PCT/IL2003/000552 patent/WO2004011035A2/en not_active Ceased
- 2003-07-03 EP EP03771237A patent/EP1575620B1/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06504274A (ja) * | 1991-01-07 | 1994-05-19 | シンジェニックス・リミテッド | 微細粒子 |
| JPH06506254A (ja) * | 1991-04-05 | 1994-07-14 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 低密度の微細球およびコンピューター断層撮影用コントラスト剤としてのそれらの使用 |
| JPH10273447A (ja) * | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
| JP2002507976A (ja) * | 1997-06-27 | 2002-03-12 | ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド | 薬理薬物の新規製剤、その製造法及びその使用法 |
Non-Patent Citations (1)
| Title |
|---|
| AVITAL,A. ET AL: "Charcoal is a sensitive, specific, and stable marker for the diagnosis of aspiration in hamsters", PEDIATR RES, vol. 51, no. 3, JPN6009043166, 2002, pages 397 - 401, XP002263602, ISSN: 0001401850 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020037100A (ja) * | 2018-08-31 | 2020-03-12 | ポール・コーポレーションＰａｌｌ Ｃｏｒｐｏｒａｔｉｏｎ | 耐塩性アニオン交換媒体 |
| JP7027673B2 (ja) | 2018-08-31 | 2022-03-02 | ポール・コーポレーション | 耐塩性アニオン交換媒体 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003242957A8 (en) | 2004-02-16 |
| WO2004011035A2 (en) | 2004-02-05 |
| WO2004011035B1 (en) | 2004-04-29 |
| AU2003242957A1 (en) | 2004-02-16 |
| US8231860B2 (en) | 2012-07-31 |
| US20050214216A1 (en) | 2005-09-29 |
| EP1575620B1 (en) | 2012-09-26 |
| EP1575620A2 (en) | 2005-09-21 |
| WO2004011035A3 (en) | 2004-03-18 |
| IL150906A0 (en) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sudhakar et al. | Biodistribution and pharmacokinetics of thiolated chitosan nanoparticles for oral delivery of insulin in vivo | |
| US5503852A (en) | Method for making self-assembling diketopiperazine drug delivery system | |
| AU608250B2 (en) | Sustained-release particulate preparation and process for preparing the same | |
| JP2865866B2 (ja) | 診断剤の製造 | |
| US20050019270A1 (en) | Formulation of powder containing nanoparticles for aerosol delivery to the lungs | |
| JP2011506077A (ja) | 親水性活性化合物の送達のための中空多重層微小球 | |
| JPH10509432A (ja) | 抗原の分配のための組成物 | |
| JP2004513886A (ja) | 固体用量ナノ粒子組成物 | |
| JP2004520409A (ja) | 乾燥粉体製剤からの放出の調節 | |
| WO2011088688A1 (zh) | 以氨基酸为稳定剂的聚合物胶束载药系统 | |
| Herbert et al. | A large-scale process to produce microencapsulated proteins | |
| PT2140882E (pt) | Agente para tratamento de doença pulmonar | |
| Mohammad et al. | Rapid lymph accumulation of polystyrene nanoparticles following pulmonary administration | |
| CN109152842A (zh) | 用于活性药物成分的基于蛋白质的赋形剂 | |
| Ali et al. | Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote | |
| JP2008518007A (ja) | 肺感染症の処置のための粒子 | |
| US8231860B2 (en) | Diagnostic microspheres | |
| JP2025102844A (ja) | ポリマー肺サーファクタント | |
| CN1878539B (zh) | 含苦味药物和pH敏感性聚合物的掩味的药物组合物 | |
| CN109395093A (zh) | 一种用于阿尔茨海默病的诊疗一体化制剂及其制备方法 | |
| CN106794156B (zh) | 微粒化胰岛素、微粒化胰岛素类似物及其制备方法 | |
| US8815294B2 (en) | Pharmaceutical compositions of dextran polymer derivatives and a carrier material | |
| JP4092587B2 (ja) | 二軸混練機を用いた乾式コーティング | |
| US20230108852A1 (en) | Controlled release system for pulmonary delivery of surfactant protein d | |
| JP4707937B2 (ja) | 薬物含有複合粒子の製造方法および経肺製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060703 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091125 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091217 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100119 |